Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about FATE, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ProHema-CB | Hematologic Malignancies | Phase 2 · NCT01627314 | Terminated |
| iPSC-derived Allogeneic Anti-CD19 1XX-CAR… | Lupus Nephritis | Phase 2 · NCT07570862 | Recruiting |
| FT839 | ANCA-Associated Vasculitis (AAV) | Phase 1/2 · NCT07800871 | Recruiting |
| ProTmune | Hematologic Malignancies | Phase 1/2 · NCT02743351 | Completed |
| Control | Hematologic Malignancies | Phase 1/2 · NCT02743351 | Completed |
| Untreated CB | Hematologic Malignancies | Phase 2 · NCT01627314 | Terminated |
| Vincristine | Diffuse Large B Cell Lymphoma | Phase 1 · NCT05934097 | Withdrawn |
| iPSC-derived Allogeneic Anti-HER2 CAR T-cells… | Advanced Solid Tumor | Phase 1 · NCT06241456 | Recruiting |
| Allogeneic iPSC-derived CD58KO Anti-MICA/MICB… | Non-Small Cell Lung Cancer | Phase 1 · NCT07216105 | Recruiting |
| Melphalan | Hematologic Malignancies | Phase 1 · NCT00890500 | Completed |
| iPSC-derived CD16/IL-15RF-expressing Anti-CD19… | Lymphoma, B-Cell | Phase 1 · NCT04245722 | Terminated |
| ProHema-CB Transplant | Metabolic Disorders | Phase 1 · NCT02354443 | Terminated |
| Single FT1050 treated UCB unit | Non-Hodgkin's Lymphoma (NHL) | Phase 1 · NCT01527838 | Completed |
| Doxorubicin | Diffuse Large B Cell Lymphoma | Phase 1 · NCT05934097 | Withdrawn |
| Bendamustine | Advanced Solid Tumor | Phase 1 · NCT06241456 | Recruiting |
| Biological: ProHema-CB | Hematologic Malignancies | Phase 1 · NCT02354417 | Terminated |
Also used in these trials (approved or third-party drugs, not FATE's own candidates): Pembrolizumab, Interleukin-2, Nivolumab, Obinutuzumab, Sirolimus, Prednisone, Trastuzumab, Rituximab, Tacrolimus Extended-Release, Atezolizumab, Avelumab, Cetuximab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
FATE holds $139.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $27.8M/quarter from operations, an estimated runway of 15 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 43 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when FATE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Redmile Group, LLC Director, 10% owner · +7.80M options |
Insider | 19,164,572 | 15.76% | 2026-11-05 |
| RedCo II Master Fund, L.P. Director, 10% owner |
Insider | 8,977,624 | 7.38% | 2025-07-02 |
| William H Rastetter Director · +142,900 options |
Insider | 642,424 | 0.53% | 2026-05-05 |
| Bahram Valamehr President and CEO, Director · +1.30M options |
Insider | 591,815 | 0.49% | 2026-08-04 |
| Cindy Tahl Chief Legal and Compliance Officer · +508,336 options |
Insider | 589,355 | 0.48% | 2026-08-04 |
| Kamal Adawi Chief Financial Officer · +450,000 options |
Insider | 93,418 | 0.08% | 2026-11-03 |
| Robert S Epstein Director · +142,900 options |
Insider | 36,331 | 0.03% | 2026-05-05 |
Share count 121,568,755 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FATE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →